Short Interest in Matinas Biopharma Holdings, Inc. (NYSEAMERICAN:MTNB) Declines By 59.9%

Matinas Biopharma Holdings, Inc. (NYSEAMERICAN:MTNB) saw a large decrease in short interest in the month of April. As of April 15th, there was short interest totaling 3,507 shares, a decrease of 59.9% from the March 31st total of 8,751 shares. Approximately 0.1% of the shares of the company are sold short. Based on an average daily volume of 29,181 shares, the days-to-cover ratio is presently 0.1 days.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Matinas Biopharma stock. DRW Securities LLC purchased a new stake in Matinas Biopharma Holdings, Inc. (NYSEAMERICAN:MTNB) during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 46,374 shares of the company’s stock, valued at approximately $27,000. DRW Securities LLC owned about 0.72% of Matinas Biopharma as of its most recent filing with the Securities and Exchange Commission. 11.77% of the stock is owned by institutional investors.

Matinas Biopharma Stock Down 1.1%

Shares of MTNB stock traded down $0.01 on Friday, reaching $0.61. The stock had a trading volume of 22,039 shares, compared to its average volume of 32,308. The firm’s 50-day moving average is $0.58 and its two-hundred day moving average is $0.81. The firm has a market capitalization of $3.91 million, a price-to-earnings ratio of -0.30 and a beta of 1.39. Matinas Biopharma has a 12 month low of $0.48 and a 12 month high of $3.09.

Matinas Biopharma (NYSEAMERICAN:MTNB) last issued its earnings results on Tuesday, March 31st. The company reported ($0.26) earnings per share (EPS) for the quarter.

About Matinas Biopharma

Matinas Biopharma Inc is a clinical?stage biopharmaceutical company that specializes in the development of novel lipid?based drug delivery platforms. Its proprietary Lipid NanoSphere (LNS) technology is designed to encapsulate water?soluble and hydrophobic therapeutic agents, enabling both oral and intravenous administration. The company’s approach aims to improve drug pharmacokinetics, enhance bioavailability and reduce systemic toxicity compared with conventional formulations.

The lead product candidate, MAT2203, is an oral formulation of amphotericin B being developed for the treatment of cryptococcal meningitis and other life?threatening fungal infections.